FDA
FDA greenlights second IL-13 antagonist for atopic dermatitis
September 19, 2024

FDA approved lebrikizumab-lbkz (Ebglyss) for the treatment of adult and pediatric patients ≥12 years of age weighing ≥40 kg with moderate to severe atopic dermatitis that's not adequately controlled with topical therapies or when those therapies aren't advisable. Ebglyss can be used with or without topical corticosteroids. Approval was supported by data from the phase 3 ADvocate 1, ADvocate 2, and ADhere trials.
TRENDING THIS WEEK